Press Releases from Neurotune AG (7 total)
Painless future: new members for Board of Directors, funding and clinical result …
Schlieren (Zurich), Switzerland, April 27, 2010. The shareholders of Neurotune AG, a Swiss biopharmaceutical company, have elected Dr. Anders Härfstrand and Heinrich Rotach as new…
Neurotune starts Phase II Clinical Trial to treat neuropathic pain
Schlieren (Zurich), Switzerland, 17th August 2009. Neurotune AG, a Swiss biopharmaceutical company, has received MCC ’s (the South African National Regulatory Agency) approval for a…
Change in the Management of Neurotune AG
Schlieren, 26th January 2009. Neurotune AG, a Swiss biopharmaceutical company, announces a change in the management. Starting March 1st 2009, Dr. Bruno Oesch will take…
Neurotune successfully completes Phase 1 Trials with its Lead Compound NT-11624
Schlieren, 15th January 2009. Neurotune AG, a Swiss biopharmaceutical company, which has recently acquired two programs in neuropathic pain, announces the successful completion of Phase…
Neurotune expands its portfolio by acquiring
Schlieren, 18th September 2008. Neurotune AG, a Swiss biopharmaceutical company, announces that the shareholders meeting, held on August 29th 2008, approved of the expansion of…
Neurotune completes next funding round
Schlieren, 29th July 2008. Neurotune AG, a Swiss biopharmaceutical company, announces the closing of the fourth funding round. Another single-digit million Swiss francs will accrue…
Neurotune starts the preclinical development of initial candidate substances for …
Schlieren, 7th November 2007. Neurotune AG, a Swiss bio-pharmaceutical company, has moved to new laboratory and office facilities at the Biotech Centre in Zurich on…
Go To Page: